{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:17:43Z","timestamp":1776860263316,"version":"3.51.2"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chemotherapy\u2010induced nausea and vomiting (CINV) is a major concern of patients with cancer, leading to suboptimal treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study assessed the emetic risk associated with intravenous and oral chemotherapy and the prophylactic antiemetic drugs by cancer type in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>We used the health services utilisation data for patients with cancer diagnosed in 2016. Patients aged at least 20\u2009years at the time of diagnosis and who started their first course of chemotherapy were included. The emetic risk of chemotherapy was determined according to the cancer type and was classified based on clinical practice guidelines. The prescription of antiemetic drugs was assessed. Overall, 172\u2009133 patients were evaluated, of whom 121\u2009103 (70.4%) received intravenous chemotherapy. High\u2010emetic\u2010risk chemotherapy (HEC) was prescribed in 46\u2009458 (27.0%) patients. HEC was prescribed most for patients with oesophageal cancer (80.3%), followed by malignant lymphoma (60.2%) and breast cancer (53.8%). Moderate\u2010emetic\u2010risk chemotherapy (MEC) was prescribed in 60\u2009528 (35.2%) patients and was mostly prescribed for small cell lung cancer (59.9%). Meanwhile, more than 50% of the chemotherapy prescribed for patients with gastric, colorectal, and pancreatic cancer was low\u2010emetic\u2010risk chemotherapy. HEC was accompanied by three\u2010drug antiemetic prophylaxis in more than 90% of patients with small cell lung, non\u2010small cell lung, breast, and oesophageal cancer, whereas only 13.5% of patients with malignant lymphoma were administered CHOP (cyclophosphamide, doxorubicin, vincristine sulphate, and prednisolone) with prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The risk of CINV differs with cancer type. HEC was less prescribed compared with MEC. Most patients received the recommended anti\u2010emetic prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1482","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T23:45:17Z","timestamp":1624837517000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real\u2010world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4732-3272","authenticated-orcid":false,"given":"Ayako","family":"Okuyama","sequence":"first","affiliation":[{"name":"Center for Cancer Control and Information Services National Cancer Center  Chuo\u2010ku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Medical Oncology National Cancer Center Hospital  Chuo\u2010ku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[{"name":"Center for Cancer Control and Information Services National Cancer Center  Chuo\u2010ku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(83)90418-2"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.507"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2019-002162"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706547"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds021"},{"key":"e_1_2_11_7_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology Antiemesis;2020.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed June 6 2020."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0951-5"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005200100273"},{"issue":"5","key":"e_1_2_11_10_1","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy\u2010 and radiotherapy\u2010induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila F","year":"2010","journal-title":"Ann Oncol"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0852-1"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0662-x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0985-8"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010548"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.06.027"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2006.05.012"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005313222209"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(02)00263-1"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20718"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-016-1069-7"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12837"},{"key":"e_1_2_11_22_1","unstructured":"National Cancer Center in Japan.Hospital\u2010Based Cancer Statistics in 2017;2018.https:\/\/ganjoho.jp\/reg_stat\/statistics\/brochure\/hosp_c_registry.html. Accessed January 18 2021."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01818-3"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"issue":"11","key":"e_1_2_11_26_1","first-page":"1312","article-title":"What do you think of the Japanese standard body surface area of 1.48? (in Japanese)","volume":"27","author":"Manabe S","year":"1999","journal-title":"Kensa to Gijyutu."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy032"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00249-9"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr042"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1188\/07.CJON.69-78"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-199507000-00009"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3730"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2146-y"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4096"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11611"},{"key":"e_1_2_11_36_1","volume-title":"JSCO Clinical Practice Guidelines 2015 for Antiemesis","author":"Japan Society of Clinical Oncology","year":"2015"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"e_1_2_11_38_1","unstructured":"Multinational Association of Supportive Care in Cancer.MASCC\/ESMO antiemetic guideline 2013.http:\/\/www.mascc.org\/antiemetic-guidelines. Accessed January 18 2021."}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1482","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1482","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:46:21Z","timestamp":1692989181000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/cnr2.1482"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1482","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,27]]},"assertion":[{"value":"2021-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1482"}}